The 13th world congress on gastrointestinal cancer: new progress of bevacizumab in treating colorectal carcinoma
- Author:
- No author available
- Journal Title:
- Cancer Research and Clinic
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1006-9801.2012.01.001
- Key Word:
- 结直肠肿瘤;贝伐单抗;治疗;Colorectal neoplasms;Bevacizumab;Therapy
Abstract： To summarize the latest study results about anti-angiogenic therapy for colorectal cancer (CRC) reported in the 13th world congress on gastrointestinal cancer, and review the latest progress of bevacizumab in treating colorectal carcinoma combined with related literatures.From the internal medicine point of view, bevacizumab is emphasized that to be applied earlier would gain benefit as soon as possible,and to be applied continuously would gain more benefit.The curative effect of second-line therapy has been confirmed renewedly.In the surgery point, bevacizumab neoadjuvant treating liver metastases in metastatic colorectal carcinoma (mCRC) can improve the disease-free rate and the operable rate significantly, and has favorable tolerance.In addition,bevacizumab can decrease the hepatic injury induced by chemotherapy safely and effectively.
- [1]Van Cutsem E,Rivera F,Berry.Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.[J].2009,20(11).
- [2]Rivera F,Cassidy J,Figer A,etc.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.[J].2008,26(12).
- [3]Mahfud M,Breitenstein S,El Badry AM,etc.Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.[J].2010,34(1).
- [4]Hurwitz H,Fehrenbacher L,Novotny W,etc.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.[J].2004,350(23).
- [5]Dorfmeister M,Koelblinger C,Herberger B,etc.Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.[J].2009,35(5).
- [6]Gruenberger T,Tamandl D,Zielinski C,etc.Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.[J].2008,26(11).
- [7]O'Dwyer PJ,Catalano PJ,Mitchell EP,etc.Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.[J].2007,25(12).
- [8]Sargent D,Purdie DM,Sugrue MM,etc.Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).[J].2008,26(33).
- [9]Masi G,Loupakis F,Salvatore L,etc.Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.[J].2010,11(9).